This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

proofread

Researchers explore present and future treatment options for hepatocellular carcinoma using immunotherapy

Treatment options for hepatocellular carcinoma using immunotherapy: present and future
Hepatocellular carcinoma (HCC) is a common cancer, and the body's immune responses greatly affect its progression and the prognosis of patients.Credit: Xun Li, Hongbin Wei, Chunlu Dong

Hepatocellular carcinoma (HCC), a prevalent form of cancer, profoundly influences the progression and prognosis of the disease through immune response mechanisms. The tumor microenvironment plays a pivotal role in fostering immune suppression and maintaining self-tolerance, which are crucial in developing and refining immunotherapy approaches.

In a comprehensive review, researchers initially delve into the characteristics of the in HCC, elucidating the predominant immunosuppressive mechanisms at play and the biomarkers pivotal for tracking the and therapeutic response. Key biomarkers such as α-fetoprotein (AFP), used for diagnosis and monitoring, and emerging molecular markers are extensively discussed.

The work is published in the Journal of Clinical and Translational Hepatology.

Central to the discussion is the transformative role of antibody-based therapies, particularly immune checkpoint inhibitors (ICIs). These therapies, which include targeting programmed cell death protein 1 (PD-1), cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), and programmed death-ligand 1 (PD-L1), have revolutionized the approach to HCC treatment.

The researchers delve into the specifics of how these therapies reinvigorate the immune system's ability to recognize and attack tumor cells, discussing their application both as monotherapies and in combination with other targeted therapies. This segment underscores the significance of ICIs in managing advanced HCC, providing new avenues for first-line and subsequent treatments.

Additionally, the review explores various cellular immunotherapies such as T cell receptor (TCR) T cell therapy and (CAR) T cell . The adaptability of these therapies to individual patient profiles illustrates the shift towards personalized medicine in oncology, aiming to optimize treatment efficacy based on unique tumor characteristics and patient immune profiles.

The potential of HCC vaccines, adjuvant immunotherapy, and oncolytic virotherapy is also thoroughly reviewed. Each of these therapeutic strategies exemplifies cutting-edge advances aiming to prime the immune system more effectively against HCC. The research team discuss the development stages of various vaccine types, their mechanisms of action, and the potential they hold in preventing recurrence and prolonging patient survival.

In conclusion, their detailed review highlights the dynamic and rapidly evolving landscape of HCC treatment. It reflects on the significant strides made in harnessing the immune system against HCC through innovative immunotherapies and sets the stage for future research that could unlock even more effective treatment modalities.

The continuous refinement of immunotherapeutic approaches promises to enhance outcomes for patients with HCC, transforming the prognosis of this challenging cancer.

More information: Hongbin Wei et al, Treatment Options for Hepatocellular Carcinoma Using Immunotherapy: Present and Future, Journal of Clinical and Translational Hepatology (2024). DOI: 10.14218/JCTH.2023.00462

Provided by Xia & He Publishing Inc.
Citation: Researchers explore present and future treatment options for hepatocellular carcinoma using immunotherapy (2024, May 22) retrieved 15 June 2024 from https://medicalxpress.com/news/2024-05-explore-future-treatment-options-hepatocellular.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Soluble immune checkpoint factors in blood as potential biomarkers of therapeutic efficacy for ICI cancer immunotherapy

 shares

Feedback to editors